{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.78","upperLimit":"27.7","value":"9.84"},{"groupId":"OG001","lowerLimit":"0.994","upperLimit":"26.7","value":"8.95"},{"groupId":"OG002","lowerLimit":"5.94","upperLimit":"8.96","value":"6.95"},{"groupId":"OG003","lowerLimit":"6.67","upperLimit":"10.9","value":"6.93"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"11"}],"units":"Participants"}],"description":"Tmax is the time to reach maximum (peak) peripheral blood or other body fluid drug concentration after single dose administration (days). Tmax, based on the transgene level data by qPCR, was summarized by Month 3 response, per Independent Review Committee assessment. The time frame of 60 months refers to the duration for which the data were reviewed to identify the time of Cmax for this measure.","dispersionType":"Full Range","groups":[{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US","id":"OG000","title":"Tisagenlecleucel - Main Cohort: CR/PR"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US","id":"OG001","title":"Tisagenlecleucel - Main Cohort: SD/PD/UNK"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"OG002","title":"Tisagenlecleucel - Cohort A: CR/PR"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"OG003","title":"Tisagenlecleucel - Cohort A: SD/PD/UNK"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS): Comprised all patients who received infusion of tisagenlecleucel with valid PK assessments.","reportingStatus":"POSTED","timeFrame":"60 months","title":"Pharmacokinetics (Pk): Tmax","type":"SECONDARY","unitOfMeasure":"days"}